Navigation Links
Common Blood Pressure Drug Safe for Heart Failure: Study
Date:4/10/2012

By Steven Reinberg
HealthDay Reporter

TUESDAY, April 10 (HealthDay News) -- Although research has suggested that the blood pressure drug losartan (Cozaar) may be tied to an increased risk of death in heart-failure patients compared to a similar medication, a new study finds that's not the case.

"Use of this and other similar drugs has been shown to reduce morbidity and mortality in patients with heart failure," said Dr. Gregg Fonarow, co-director of the Preventative Cardiology Program at the University of California, Los Angeles, and director of the Ahmanson-UCLA Cardiomyopathy Center, commenting on the study results.

An earlier observational study in patients with heart failure suggested that losartan was associated with higher risk of death compared to the drug candesartan (Atacand), he said.

"There were, however, a number of limitations to this prior study that could have biased these results, including differences in dosing and treating physicians," said Fonarow, who was not involved in the studies.

The new research, conducted in Denmark, finds no meaningful difference in survival among heart failure patients treated with losartan or candesartan, he said.

"This study also finds for both agents that the use of higher doses, as recommended in guidelines, is associated with better outcomes than the use of lower doses," Fonarow said.

The report was published in the April 11 issue of the Journal of the American Medical Association.

Heart failure, also called congestive heart failure, means the heart is unable to pump blood to the rest of the body the way it should.

For the study, Henrik Svanstrom, from the Statens Serum Institute in Copenhagen, and colleagues collected data on nearly 6,500 heart failure patients who had recently started taking losartan (4,397 patients) or candesartan (2,082 patients).

Both are a type of drug called angiotensin II receptor blockers (ARBs).

During follow-up, 2,378 participants died -- 330 taking candesartan and 1,212 patients taking losartan, the researchers found.

However, there was no significant increased risk of all-cause death or cardiovascular death associated with losartan compared to candesartan, the researchers said.

But dosage was important, the team said. The study found twice the risk of death with low-dose losartan compared to high-dose candesartan. Medium-dose losartan and low-dose candesartan also had a higher risk of death, but high-dose losartan had no increased death risk compared to high doses of candesartan.

"Our data provide a more detailed insight into the complexity of the association between losartan use and mortality risk in heart failure," the researchers concluded.

"These findings do not support the hypothesis of differential effects of specific ARBs in patients with heart failure," they added.

Dr. David Friedman, chief of heart failure services at North Shore-LIJ Health System's Plainview Hospital in Plainview, N.Y., said, "These medications are very helpful in heart failure patients."

Friedman noted that those in the losartan group were older and sicker, which may explain why more of them died.

These patients could only tolerate lower doses of losartan, and because they were sicker they were more likely to die than patients who could tolerate higher starting doses of candesartan, he said.

More information

For more on heart failure, visit the American Heart Association.

SOURCES: Gregg Fonarow, M.D., director, Ahmanson-UCLA Cardiomyopathy Center, and co-director, UCLA Preventative Cardiology Program, Los Angeles; David A. Friedman, M.D., chief, heart failure services, North Shore-LIJ Health System's Plainview Hospital, Plainview, N.Y.; April 11, 2012, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Adapting to clogged airways makes common pathogen resist powerful drugs
2. A common cholesterol drug fights cataracts, too
3. U.S. National Guard Connects Nationwide with Desktop Alert's Command and Control Mass Notification Systems and Common Alerting Protocol (CAP)
4. US21, Inc. is Granted a Wholesale Distributor Permit from the Commonwealth of Virginia Board of Pharmacy
5. New therapeutic target for most common solid cancer in childhood?
6. Migraine More Common in Women with MS
7. Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis
8. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
9. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
10. Common osteoporosis drugs are associated with a decrease in risk of breast cancer
11. Commonwealth Leverage Group and Helium Interactive Form HIE Go-To-Market Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common Blood Pressure Drug Safe for Heart Failure: Study
(Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent Care ... MD Now’s 28th facility overall and marks the urgent care center's eighth location in ... North of The Falls shopping mall. The new clinic offers a wide array of ...
(Date:6/23/2017)... ... ... American Farmer, will feature Chr. Hansen, Inc (CHR Hansen) in an upcoming episode ... Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for more info. ... 1874 after a groundbreaking discovery of how to industrialize enzymes. Rooted in science and ...
(Date:6/23/2017)... Chicago, IL (PRWEB) , ... June 23, 2017 ... ... insurance management assistance and financial planning services to communities in the greater Chicago ... Children’s Association to offer assistance to underprivileged youth in Chicago. , Founded in ...
(Date:6/23/2017)... ... June 23, 2017 , ... Moore Insurance, ... area with access to asset protection and financial planning services, is teaming up ... improving the lives of children with cancer and other chronic diseases. , The ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... is pleased to welcome Whipple & Company as its newest Partner Firm. Headquartered ... of balancing their clients’ risk while tailoring optimized benefit packages that strengthen the ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
(Date:5/29/2017)... Israel, May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... technology which enables the functional selection of stem cells, ... for the first quarter ended March 31 st , ... our accomplishments in the first quarter of 2017," said ... quarter, we announced the treatment of the first blood ...
(Date:5/22/2017)... VALLEY COTTAGE, N.Y. , May 22, 2017 ... natural antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of ... in plain English, the results of a clinical ... after one year treatment with Gene-Eden-VIR/Novirin in individuals ... is important to note that there are no ...
Breaking Medicine Technology: